Ładuje się......
Pegylated Interferon for the Adjuvant Treatment of Melanoma: FDA Approved, but What Is Its Role?
The article by Herndon and colleagues on the approval of peginterferon-alfa-2b for the adjuvant treatment of patients with resected node-positive melanoma, published in this issue of The Oncologist, is examined, and the relevance of this therapy in clinical practice discussed.
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
AlphaMed Press
2012
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3481887/ https://ncbi.nlm.nih.gov/pubmed/23002125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0368 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|